Literature DB >> 12420216

Src activation regulates anoikis in human colon tumor cell lines.

T Christopher Windham1, Nila U Parikh, Doris R Siwak, Justin M Summy, David J McConkey, Alan J Kraker, Gary E Gallick.   

Abstract

Src is a non-receptor protein tyrosine kinase, the expression and activity of which is increased in >80% of human colon cancers with respect to normal colonic epithelium. Previous studies from this and other laboratories have demonstrated that Src activity contributes to tumorigenicity of established colon adenocarcinoma cell lines. Src participates in the regulation of many signal transduction pathways, among which are those leading to cellular survival. In this study, we addressed the potential role of Src activation to a specific aspect of tumor cell survival, resistance to detachment-induced apoptosis (anoikis). Using five colon tumor cell lines with different biologic properties and genetic alterations, we demonstrate that expression and activity of Src corresponds with resistance to anoikis. Enforced expression of activated Src in subclones of SW480 cells (of low intrinsic Src expression and activity) increases resistance to anoikis; whereas decreased Src expression in HT29 cells (of high Src expression and activity) by transfection with anti-sense Src expression vectors increases susceptibility to anoikis. In contrast, increasing or decreasing Src expression had no effect on susceptibility to staurosporine-induced apoptosis in attached cells. PD173955, a Src family-specific tyrosine kinase inhibitor, increases the susceptibility of HT29 cells to anoikis in a dose- and time-dependent manner. Increasing Src expression and activity led to increased phosphorylation of Akt, a mediator of cellular survival pathways, whereas decreasing Src activity led to decreased Akt phosphorylation. In colon tumor cells with high Src activity, the PI3 kinase inhibitor LY 294002 sensitized cells to anoikis. These results suggest that Src activation may contribute to colon tumor progression and metastasis in part by activating Akt-mediated survival pathways that decrease sensitivity of detached cells to anoikis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12420216     DOI: 10.1038/sj.onc.1205989

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  70 in total

1.  RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells.

Authors:  Takahide Ota; Masayo Maeda; Shiho Sakita-Suto; Xinwen Zhou; Manabu Murakami; Tsutomu Takegami; Masaaki Tatsuka
Journal:  Clin Exp Metastasis       Date:  2006-11-17       Impact factor: 5.150

Review 2.  Active participation of endothelial cells in inflammation.

Authors:  Joan M Cook-Mills; Tracy L Deem
Journal:  J Leukoc Biol       Date:  2005-01-03       Impact factor: 4.962

3.  Apoptosis in cancer: archaeology, functional relevance and exploitation in novel treatment strategies.

Authors:  E F Gaffney
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

4.  Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis.

Authors:  Nicholas T Woods; Hirohito Yamaguchi; Francis Y Lee; Kapil N Bhalla; Hong-Gang Wang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

5.  The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.

Authors:  Danislav S Spassov; Frederick L Baehner; Ching Hang Wong; Stephen McDonough; Mark M Moasser
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 6.  Understanding micrometastatic disease and Anoikis resistance in ewing family of tumors and osteosarcoma.

Authors:  Sandra J Strauss; Tony Ng; Ariadna Mendoza-Naranjo; Jeremy Whelan; Poul H B Sorensen
Journal:  Oncologist       Date:  2010-05-17

Review 7.  Is there a genetic signature for liver metastasis in colorectal cancer?

Authors:  Cristina Nadal; Joan Maurel; Pere Gascon
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Apoptosis-associated tyrosine kinase 1 inhibits growth and migration and promotes apoptosis in melanoma.

Authors:  Shuang Ma; Brian P Rubin
Journal:  Lab Invest       Date:  2014-03-03       Impact factor: 5.662

Review 9.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

10.  Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Authors:  Muling Mao; Feng Tian; John M Mariadason; Chun C Tsao; Robert Lemos; Farshid Dayyani; Y N Vashisht Gopal; Zhi-Qin Jiang; Ignacio I Wistuba; Xi M Tang; William G Bornman; Gideon Bollag; Gordon B Mills; Garth Powis; Jayesh Desai; Gary E Gallick; Michael A Davies; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.